News Hub | News Direct

Professional Services

Architecture CRM/Customer Service Consulting Government & Policy Human Resources Intellectual Property/Trademark/Patent Law Legal
Article thumbnail News Release

The Bermuda Business Development Agency (BDA) Leads Economic Growth as EIRC Initiative Surpasses $500 Million Milestone

Bermuda Business Development Agency

October 10, 2024 – The Bermuda Business Development Agency (BDA) is pleased to announce that the Economic Investment Residential Certificate (EIRC) initiative has surpassed $500 million in investments. This milestone reinforces Bermuda’s position as a premier destination for global investors, showcasing the EIRC’s pivotal role in driving sustained economic growth while enhancing the island’s appeal to high-net-worth individuals seeking both exceptional investments and an unmatched island lifestyle. Since its launch in 2021, The BDA has successfully provided concierge services for all EIRC applicants, guiding them through each phase of the process and ensuring a smooth, seamless experience. This tailored approach has been instrumental in driving economic growth, attracting affluent investors from around the world, including the U.S., U.K., Canada, and Spain. With a minimum investment of $2.5 million, participants gain permanent residency in Bermuda and the flexibility to invest in real estate, new and existing local businesses, Government bonds (previously offered), or social causes. To date, 58 approved applications have driven substantial capital into local enterprises and the property market. The EIRC does however offer more than financial benefits; many certificate holders are drawn to Bermuda because of personal connections, whether through birth, marriage, or long-standing relationships with the island. As a result, these stakeholders are not solely investing capital—they have become part of Bermuda’s community. Data shows that nearly half of a country’s economic growth typically originates from individuals already embedded in the community, and Bermuda is no different. By becoming part of the island’s fabric, these stakeholders unlock even greater opportunities for investment and growth, driving Bermuda’s continued economic success. The Honourable Jason Hayward, Minister of Economy and Labour, commented on the programme's success: "The EIRC initiative has proven to be a vital tool for stimulating economic development in Bermuda. By attracting high-net-worth individuals who are not only investing but also establishing Bermuda as their home, we are creating long-term opportunities for the island. Surpassing the $500 million mark is a significant achievement, and we are confident that the BDA and EIRC programme will continue to contribute positively to Bermuda’s economic growth." Kyle Rogers, Research and Intelligence Manager at the BDA, is also responsible for overseeing the concierge service that supports applicants throughout the entire EIRC process. He ensures seamless management of the certificates, providing crucial guidance from initial inquiry, through comprehensive candidate evaluation, to final approval. He stated, "Reaching $500 million is a testament to Bermuda’s unique offering as both a business hub and an exceptional place to live. The EIRC initiative continues to generate significant value by attracting capital and new residents who are committed to the island’s long-term success. We are excited about the programme’s growth and the bright future ahead." Of the total $500 million investment, $212 million has been directed towards new businesses, $231 million into real estate, $49 million into existing local enterprises, $2.6 million into Government bonds, and $6 million into social ventures deemed beneficial to Bermuda and subject to the Minister’s approval. Jonathan Halata, a developer, investor, and successful EIRC applicant, shared his experience: "As Canadians and Brits, my family has been connected to Bermuda since the 1970s. The EIRC wasn’t just about investing money; it was about building a life for my husband and daughter, and contributing to the community my family has become part of." "My investment in Bermuda extends far beyond financial returns—it's about contributing to the development of premier assets like hotels and tourism infrastructure. Island Realty projects like Azura and Nautilus have brought something unique to Bermuda and created dozens of jobs, which are vital for both airlift and the livelihoods of Bermudians. "I see a direct link between the EIRC programme and Bermuda’s future growth. It’s not just about selling homes—it’s about creating lasting opportunities. Multiplying our experience by 10, 50, or 100 could generate significant new jobs for Bermudians." "The EIRC certificate process was much easier than I expected, especially knowing the complexities with immigration and work permits. The BDA’s white-glove service, with Kyle’s personal attention to detail, made a tremendous difference. They delivered exactly what was promised, with a ribbon on top." For more information on the Economic Investment Residential Certificate and how to apply, visit bda.bm. Media Contact: Simone Gibbons Head of Marketing, Communications & Events D. +1 441 297 7774 | M. +1 441 707 0038 | E: simone@bda.bm The Bermuda Business Development Agency (BDA) encourages direct investment and helps companies start up, re-locate, or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Contact Details Bermuda’s Business Development Agency (BDA) +1 441-707-0038 info@bda.bm Company Website https://bda.bm

October 10, 2024 02:35 PM Eastern Daylight Time

Article thumbnail News Release

NAVEX Lance « La Conformité en France : Le Guide Ultime »

NAVEX Global

NAVEX, le leader mondial des logiciels et services de gestion de la gouvernance, des risques, et de la conformité (GRC), a annoncé le lancement de « La conformité en France: Le guide ultime ». NAVEX aide plus de 13 000 entreprises à travers le monde à gérer et à atténuer les risques en toute confiance. Les programmes de conformité doivent jouer un rôle crucial quotidien à la fois pour garantir le respect des réglementations et pour cultiver une culture éthique. Le lancement d’alerte étant un élément clé de ces efforts. Jan Stappers, directeur des solutions réglementaires chez NAVEX, affirme: « Les organisations pourraient passer à côté d’opportunités si elles ne disposent pas d’un canal pour alerter les gens des risques ou dangers potentiels. Le lancement d’alerte est la meilleure source d’informations sur les actes répréhensibles réels ou potentiels, mais avec autant de réglementations à respecter, le risque actuel est que les entreprises effectuent des exercices de vérification plutôt que d’adopter une approche plus intégrée. » La première partie du guide offre un aperçu détaillé du paysage actuel du lancement d’alerte en France, y compris une explication du contexte culturel et d’informations sur la façon dont le système français se compare à d’autres dans le monde. Une plongée dans les données de lancement d’alerte montre que les niveaux de signalement français augmentent mais restent bas par rapport aux normes européennes, tandis que les rapports français sont moins susceptibles d’être anonymes et ont tendance à prendre plus de temps à traiter que ceux d’autres pays. De plus, la deuxième partie de ce guide présente le cadre réglementaire français, en mettant l’accent sur les défis critiques de conformité et les questions extraterritoriales qui peuvent être particulièrement difficiles à maîtriser pour les entreprises. Au sens large, le respect de toutes les réglementations existantes est devenu un défi majeur, de nombreuses entreprises ne disposant pas de la bande passante nécessaire pour suivre l’évolution du paysage réglementaire. Enfin, la troisième partie de ce rapport couvre en profondeur les lois et réglementations qui sont importantes pour toute entreprise cherchant à naviguer dans le paysage de la conformité et de l’alerte professionnelle en France. La France et le monde: les principales différences à savoir selon les données de NAVEX La France a un taux de lancement d’alerte inférieur à celui de l’Allemagne ou à la moyenne européenne, avec des niveaux de signalement en hausse mais toujours inférieurs aux normes régionales. Il existe des preuves que les rapports français sont plus susceptibles d’être justifiés, avec plus de la moitié s’avérant vrais contres seulement un tiers qui sont attestés en Allemagne. Les rapports français sont beaucoup moins susceptibles d’être anonymes que les pratiques courantes dans d’autres pays et régions. Seulement la moitié des alertes françaises sont effectuées de manière anonyme, contre plus de deux tiers au Royaume-Uni, ce chiffre n’étant qu’en légère hausse ces dernières années. Il est suggéré que les personnes soulevant des préoccupations aujourd’hui ne le feront que s’ils soient plus confiants et directs dans leurs allégations. Les questions de RH, de diversité et de lieu de travail dominent les rapports en France. Les questions de RH, de harcèlement et de discrimination combinées ont représenté près de deux plaintes sur trois adressées aux entreprises françaises en 2023, tandis que les signalements liés aux conflits d’intérêts étaient les quatrièmes problèmes les plus fréquents et représentaient 10 % des signalements. Cliquez- ici pour télécharger le guide ultime de la conformité en France. À propos de NAVEX Des milliers de clients du monde entier font confiance à NAVEX pour les aider à atteindre les résultats qui comptent le plus. En tant que leader mondial des logiciels et services de gestion intégrée des risques et de la conformité, nous proposons nos solutions par le biais de la plateforme NAVEX One, le système d’information le plus complet du secteur en matière de gouvernance, de risque et de conformité (GRC). NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details NAVEX Anita Lo +1 617-388-5773 anita.lo@navex.com Company Website https://www.navex.com/fr-fr/

October 10, 2024 09:00 AM Eastern Daylight Time

Article thumbnail News Release

Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit

Silexion Therapeutics Corp

Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced its participation in the 2024 Maxim Healthcare Virtual Summit, scheduled to take place from October 15 to 17, 2024. Ilan Hadar, Chief Executive Officer and Dr. Mitchell Shirvan, Chief Scientific and Development Officer will join a fireside chat hosted by Jason McCarthy, Senior Managing Director and Head of Biotechnology Research at Maxim Group, on Thursday, October 17, 2024, at 9:30am ET. The event will be streamed live on M-Vest and accessible to members by clicking here or via following link: https://m-vest.com/events/healthcare-10152024. The Company’s management team will be available for one-on-one meetings throughout the summit. Interested investors are encouraged to contact their Maxim representative to schedule a meeting. About Silexion Therapeutics: Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: https://silexion.com Contact Details Silexion Therapeutics Corp Ms. Mirit Horenshtein Hadar, CFO mirit@silexion.com ARX | Capital Markets Advisors North American Equities Desk silexion@arxadvisory.com

October 09, 2024 04:30 PM Eastern Daylight Time

Article thumbnail News Release

MOU BETWEEN THE U.S. AND PERU PROVIDES A STEPPING STONE FOR MINING COMPANIES AT MINEXPO 2024

Promperu

With the new memorandum of understanding (MOU) signed between the United States of America (U.S.) and Peru, over 300 delegates -- the largest Peruvian business delegation ever – showed up in force at MINEXPO 2024, the premiere mining conference for the industry. Sponsored by the National Mining Association, it was held recently in Las Vegas. This underscores the importance of the relationship between the U.S. and Peru, a top producer of crucial minerals such as copper, lithium, silver and rare earth elements, essential for manufacturing a range of products, including cell phones, computers, and renewable energy technologies. As the U.S. transitions to green energy, these minerals are vital for producing batteries, electric vehicles, and other clean technologies, potentially saving the country billions in energy costs and enhancing energy independence. “Expanding the supply access to crucial minerals including copper and lithium, both of which are required for green energy technology, is essential,” emphasized Alvaro Silva-Santisteban, the ​ Executive ​ ​ Director ​ of PROMPERU in the U.S., which is the Investment, Trade and Tourism Commission of Peru. “As a result, Peru fortifies its world leadership as a natural location for mining companies seeking to expand production.” The MOU, which was finalized last August, opens the door to more mining opportunities for Foreign Direct Investment (FDI) and clears the way for the U.S. and Peru to partner on the extraction of a small portion of Peruvian green technologies. “Peru, with its vast reserves of copper, zinc, lithium, and other important minerals, is an invaluable partner for the U.S. as they strive to meet this immense growth in demand,” said José W. Fernández, U.S. Undersecretary for Economic Growth, Energy, and the Environment, after the signing. The cooperative effort strengthens international investment in strategic resources essential to not only product manufacturing, but green technology as well. “Almost every electric car and smartphone use these minerals, and in Peru, the vast majority of these crucial metals are yet to be mined,” Silva-Santisteban added. “This is a boon for our planet’s future and the Peruvian economy.” According to the Ministry of Energy and Mines, Peru is the world’s second-largest exporter of copper, ranks third for silver, and holds massive reserves of gold, zinc, and lead. Peru holds more than six tons of lithium reserves and the production of eight crucial ‘green minerals,’ minerals that are needed to support the transition to clean energy technologies, such as iron, lead, molybdenum, indium and graphite. “With the MOU and our participation in MINEXPO, bringing together knowledgeable exporters of services, minerals and machinery, the synergies will create an opportunity that will strengthen foreign investment in strategic resources for green technology, which will lead to even greater international developments,” said Silva-Santisteban. Peru, holding the second-largest ore reserves for both silver and copper in the world, also accounts for substantial global reserves of gold (5.6%), zinc (8%), lead (6.2%), and other metals. Peru has 31 copper projects across 14 regions, representing a potential investment of nearly $39.8 billion. Minister of Energy and Mines, Rómulo Mucho Mamani, highlighted that Peru holds 11% of the world's copper reserves and that these projects could yield an additional two million tons of copper. ### For more information please visit: www.PROMPERU.gob.pe Contact Details The Hoyt Organization Kelly Reynolds +1 310-343-3197 kreynolds@hoytorg.com

October 08, 2024 09:00 AM Pacific Daylight Time

Image
Article thumbnail News Release

NAVEX Unveils Curated AI Content Library to Simplify Compliance and Risk Mitigation

NAVEX Global

NAVEX, the global leader in integrated risk and compliance management software, introduces its new AI-focused content library designed to help organizations address the rapidly evolving landscape of Artificial Intelligence (AI) regulations and frameworks. As AI technologies become part of daily operations, many organizations find themselves entering uncharted waters regarding effective AI governance. According to Forrester’s September 2023 Artificial Intelligence Pulse Survey, 56% of AI decision-makers said their organization will use generative AI (genAI) in the next 12 months for internal or customer-facing production applications for employee productivity. The stakes are rising, and navigating these challenges without a clear framework can feel overwhelming, leaving companies vulnerable to risks. NAVEX plays a critical role by enabling companies to implement strong controls, automate workflows, and perform comprehensive testing. This approach simplifies complex challenges and transforms them into strategic opportunities. NAVEX’s content library is continuously curated to cover international and industry-specific AI regulations, including emerging standards and compliance requirements. By leveraging this resource, customers can ensure their AI initiatives align with ethical guidelines and regulatory mandates. A.G. Lambert, Chief Product Officer at NAVEX, captures the pivotal moment many organizations face: "As AI technologies revolutionize industries, companies find themselves standing at a crossroads, navigating the intricate landscape of effective AI governance. Our AI content not only empowers risk management professionals to establish crucial controls but also enhances efficiency by automating compliance processes. This dual approach enables organizations to embrace AI technology with confidence, transforming challenges into opportunities for growth and innovation." Key features of the NAVEX AI content library include: Centralized AI Regulatory Resources: Access a consolidated library of global AI regulations and industry-specific guidelines. Streamlined Control Development: Simplify the process of creating and implementing AI-specific controls to align with emerging regulations. Automated Compliance Monitoring: Leverage automation to track compliance requirements and ensure adherence through continuous control testing. Enhanced Risk Mitigation: Identify and mitigate AI-related risks proactively using structured regulatory frameworks. Future-Proof Compliance Strategy: Stay ahead of evolving AI laws and standards, ensuring the organization remains compliant and competitive. NAVEX is enhancing AI governance with its NAVEX One platform that streamlines the process of developing and distributing AI-related policies, ensuring companies stay aligned with fast-changing compliance requirements in the AI landscape. Should employees or third parties have AI-related issues or concerns, the NAVEX One platform offers employees a secure solution to report them. This proactive approach helps organizations identify and mitigate potential risks early on. The NAVEX content library offers over 400 regulations and compliance frameworks, continuously expanding to meet the demands of an evolving regulatory environment. This extensive resource includes critical AI regulations such as the EU AI Act, NIST AI Risk Management Framework, and the Colorado Artificial Intelligence Act. As AI governance becomes increasingly critical, NAVEX integrates AI training, incident management, and policy management into this comprehensive resource, ensuring organizations stay ahead of compliance requirements. With real-time updates, businesses can select tailored content to meet emerging AI regulatory standards, providing the tools to navigate current and future compliance challenges effectively. This seamless integration helps organizations maintain a proactive risk and compliance posture while leveraging cutting-edge technologies. The new AI content library is now available as part of NAVEX’s Integrated Risk Management solution. For more information, visit NAVEX’s Website. NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details Navex Global +1 617-388-5773 scott.levesque@navex.com Company Website https://navex.com

October 08, 2024 08:00 AM Eastern Daylight Time

Article thumbnail News Release

Danmarks Blomstrende Spille- og casino-scene: Nye Innovationer og Ansvarligt spil

AM Europe

København, Danmark - [October, 4th] - Danmarks spil- og gamblingkultur fortsætter med at blomstre, præget af innovative nye spil, spændende begivenheder og et stærkt engagement i ansvarligt spil. Med en rig spilhistorie omfavner danske spillere de nyeste trends, samtidig med at de nyder godt af en robust lovgivningsmæssig beskyttelse, der sikrer et sikkert spilmiljø. Spændende nye spil lanceres dette efterår Denne sæson vil flere spilleselskaber lancere spændende nye titler, der lover at forbedre spiloplevelsen for danske spillere. Fra fordybende online slots til engagerende live dealer-spil kan spillerne se frem til banebrydende grafik og innovativt gameplay. Bemærkelsesværdige udgivelser inkluderer " Viking Quest ", en spændende eventyrautomat, der fejrer Danmarks rige historie, og "Nordic Roulette", der kombinerer klassisk casino-spænding med et tydeligt dansk twist. Store casino-begivenheder i horisonten Casino Copenhagen gør klar til sit årlige "Danish Poker Championship", hvor spillere fra hele landet vil konkurrere om pengepræmier og den eftertragtede mesterskabstitel. Arrangementet finder sted den 15.-17. november og vil tiltrække både erfarne professionelle og entusiastiske amatører. Deltagerne kan forvente en weekend fyldt med dygtighed, strategi og kammeratskab, der afspejler den livlige ånd i Danmarks pokersamfund. Forpligtelse til ansvarligt spil Danmark er stolt af sine stærke lovgivningsmæssige rammer, som sikrer, at spilaktiviteter udføres retfærdigt og ansvarligt. Den danske Spillemyndighed fører tilsyn med alle spiloperationer og håndhæver strenge regler, der beskytter spillerne. Dansk lov kræver, at operatørerne giver klar information om risici ved spil, så spillerne kan træffe informerede valg. Desuden er initiativer, der har til formål at fremme ansvarligt spil, i højsædet i det danske spillelandskab. Spillere opfordres til at sætte grænser for deres forbrug, og mange operatører tilbyder muligheder for selvudelukkelse for at hjælpe dem, der måske har brug for en pause fra spil. What is ROFUS? ROFUS, det danske onlinespilleregister, er et vigtigt initiativ, der er etableret for at fremme ansvarligt spil i hele Danmark. ROFUS administreres af Spillemyndigheden og giver spillere mulighed for frivilligt at udelukke sig selv fra at deltage i onlinespil, siger spil-uden-om-rofus.net. Denne brugervenlige platform giver enkeltpersoner mulighed for at tage kontrol over deres spillevaner ved at sætte personlige grænser eller vælge en midlertidig eller permanent selvudelukkelse. ROFUS blev lanceret for at forbedre spillernes sikkerhed og sikrer, at personer, der kan være i fare for at få spilleproblemer, kan søge hjælp og få adgang til støtte. Ved at stille et centralt register til rådighed fremmer det ikke kun en kultur med ansvarligt spil, men styrker også integriteten i spilindustrien i Danmark. En kultur af fællesskab og sjov Danske spillere nyder godt af en unik blanding af sociale spiloplevelser, både online og på fysiske kasinoer. Kammeratskabet mellem spillerne er et afgørende træk ved den danske spillekultur, hvor deling af strategier og fejring af gevinster skaber et indbydende miljø. I takt med at branchen udvikler sig, er Danmark fortsat forpligtet til at fremme en sikker og fornøjelig spilleatmosfære. Med nye spil, spændende events og ansvarlige regler på plads ser fremtiden for spil og gambling i Danmark lysere ud end nogensinde. Contact Details Oliver Damgaard +45 27 35 72 27 oliver@cspeed.com

October 04, 2024 11:45 PM Eastern Daylight Time

Image
Article thumbnail News Release

Market Alert: Silexion Therapeutics (NASDAQ: SLXN) Sees Record Volumes Following Breakthrough Preclinical Data for SIL-204

Global Markets News

Shares of Silexion Therapeutics (NASDAQ:SLXN) are seeing significatnly today after the company announced promising new preclinical data for its next-generation siRNA candidate, SIL-204. The stock saw a significant initial of price spike of over 50% in pre-market activity as investors responded to the latest developments in Silexion's RNA interference (RNAi) platform, which targets KRAS-driven cancers. As of now, volume is at record highs, currently standing at over 50 million shares today. The company revealed that SIL-204, an extended-release microparticle formulation, demonstrated substantial tumor reduction and necrosis in mouse models of pancreatic cancer bearing the KRAS G12D mutation—one of the most common mutations found in pancreatic cancer patients. This latest data builds on a string of recent successes for Silexion, including its September 24 announcement of results from the Phase 2 trial for its first-generation product, LODER™, which showed significant improvements in tumor resectability among non-resectable pancreatic cancer patients. Alongside the new preclinical results, Silexion has recently reported plans to begin toxicology studies for SIL-204 in preparation for Phase 2/3 clinical trials expected to commence in the first half of 2026. The company is also expanding the application of its siRNA technology to colorectal cancer models, reflecting its broader ambitions to target multiple KRAS-driven cancers, which are notoriously difficult to treat with conventional therapies. While stock price has pulled back since premarket, The spike in Silexion’s market activity as marked by these record high volumes (according to market data) may highlight the growing market interest in the company’s novel approach to tackling cancers with high unmet medical needs, particularly its focus on KRAS mutations, which are common across a variety of aggressive cancers, including pancreatic and colorectal cancer. Silexion’s continued momentum in the precision oncology space potentially positions it as a leading player in the development of next-generation RNAi therapies. With its promising pipeline and recent positive developments, the company seems to be gaining attention as it advances toward clinical trials that could offer new hope for patients battling some of the deadliest cancers. Click here to read Silexion's full announcement *** This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [https://justpaste.it/ab9dn/pdf]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

October 01, 2024 11:47 AM Eastern Daylight Time

Article thumbnail News Release

drive21, Van Wagner Collaborate to Elevate In-Venue Branding and Fan Engagement Across College Athletics

drive21

drive21, a leader in experiential design and marketing solutions, today announced a strategic relationship with leading collegiate athletics marketing agency, Van Wagner to become a preferred experiential graphic design and implementation provider for Van Wagner. Van Wagner is recognized for its expertise in collegiate sponsorship sales and multi-media rights and will collaborate with drive21 to redefine branding strategies, drive revenue growth, and create Name, Image and Likeness (NIL) execution opportunities in the collegiate sports industry. Through this relationship, Van Wagner’s collegiate clients will be afforded advantageous pricing and access to drive21’s suite of services to provide innovative branding and design solutions across their venues; driving innovative solutions that bridge the gap between brand aspirations and reality, creating immersive environments that resonate with audiences and drive tangible business results. "This relationship represents a significant step forward in our mission to transform sports and entertainment venues into impactful environments that are also powerful marketing tools," said Warren Godridge, drive21 Founder and President. "By collaborating with Van Wagner, we can leverage our creativity and expertise to deliver a consistent brand experience across all venues, enhancing the value for brands, universities, and fans alike." “Traditional approaches often focus solely on aesthetics and overlook the potential to maximize partnership, sponsorship and NIL opportunities, leaving untapped value on the table” said John Libro, Head of Sports and Entertainment at drive21. “Working with Van Wagner College will allow us to push the boundaries of experiential design and transform collegiate athletic facilities into dynamic revenue-generating tools that engage fans and drive real business growth.” This relationship may also offer an even more comprehensive solution to collegiate clients by providing new NIL revenue streams. Through this collaboration with drive21, a portion of the facility’s expenditure can be reallocated to the universities’ NIL efforts. This allows universities to offer a more engaging experience for athletes and fans while creating dynamic environments supporting athletic performance, fan engagement and brand partnerships. "drive21’s ability to seamlessly integrate brand experiences into our facilities is a game-changer for our clients,” said Mark Donley, Chief Revenue Officer at Van Wagner College. “Through our arrangement with drive21, our university clients have an opportunity to access the expertise of drive21 to not only enhance their facilities but also ensure a consistent and high-quality experience for a variety of initiatives at an advantageous rate. It's truly a win-win-win scenario." The first major joint effort was a collaboration at Florida International University for the brand implementation of the newly named Pitbull Stadium. drive21 and Van Wagner played a key role in creating cohesive branding for the first college athletic venue named after a musician, exampling the transformative potential of experiential design and strategic branding. To learn more about the partnership, or drive21’s sports, entertainment and hospitality solutions, please visit www.drive21.com. About drive21 drive21 elevates the sports, entertainment, and hospitality industries by delivering one-of-a-kind branded venue experiences. A leader in experiential design and marketing solutions, drive21 bridges the gap between imagination and reality to deliver functional and impactful environments through design, fabrication, implementation, and holistic project management. Servicing organizations including MLB, MLS and NCAA institutions, drive21 helps its clients maximize partnership and sponsorship revenue and turns ordinary environments into extraordinary works of art. For more information, visit www.drive21.com. About Van Wagner Van Wagner is a leading sports advertising and entertainment agency with global expertise in filmed and live entertainment, sponsorship sales, multi-media rights, and aerial advertising. Van Wagner creates, advises, and sells for world-class teams, leagues, brands, and properties. An innovator in the sports and media business, Van Wagner is a global leader in high-impact broadcast visible signage throughout the MLB, NBA, NCAA, and international soccer, sponsorships sales, college multi-media rights, and in-venue content production at the world’s biggest sporting events. For more information, visit www.vanwagner.com. Contact Details Hot Paper Lantern Jackson Gaskins jgaskins@hotpaperlantern.com Company Website https://drive21.com

September 25, 2024 08:00 AM Eastern Daylight Time

Article thumbnail News Release

Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian

Global Markets News

Summit Therapeutics (NASDAQ: SMMT) recently captured headlines with the release of its Phase 3 data for ivonescimab, a targeted NSCLC therapy that has generated substantial buzz. The results from its trial conducted in China showed a dramatic 49% reduction in the risk of disease progression or death compared to Merck’s Keytruda, signaling a potentially disruptive force in NSCLC treatment. However, the news wasn’t without its concerns—since the trial data originates from China, there are questions about its applicability to broader, global populations. As noted by BMO Capital Markets’ Evan Seigerman: “Results may or may not be generalizable beyond the China-focused patient population initially assessed.” Despite this, Summit’s valuation has risen by over 100%, now approximating $19 billion. With such a high valuation, the company could see limited room for further significant gains, leading many in the industry to explore other emerging opportunities in precision oncology. Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising initial results and could see similar success in the future if they were to report positive results. These emerging players are worth watching for those interested in following precision oncology drug candidates and pipelines. Among them are precision oncology innovators such as Silexion Therapeutics, Nuvectis Pharma, and Scorpion Therapeutics, which we discuss below. Silexion Therapeutics: Disrupting the KRAS-Driven Cancer Space Silexion Therapeutics (NASDAQ: SLXN) is another under-the-radar player in the precision oncology space, with a focus on KRAS-driven cancers—a notoriously difficult target in oncology. While current small-molecule KRAS inhibitors are making progress, they are often limited to specific mutations, such as KRAS G12C, which accounts for a small percentage of cancers. Silexion’s RNA interference (RNAi) approach offers a broader solution, targeting a wider spectrum of KRAS mutations, particularly in pancreatic cancer, one of the deadliest and most treatment-resistant cancers. At the heart of Silexion’s approach is its LODER™ platform, which delivers siRNA directly to the tumor site, silencing KRAS mutations at the genetic level. This localized delivery not only increases efficacy by concentrating the treatment in the tumor, but it also reduces systemic side effects. Silexion’s next-generation candidate, SIL-204, is an optimized siRNA formulation designed to target pan-KRAS G12x mutations, positioning it to treat a broader range of KRAS-driven cancers beyond pancreatic cancer, such as lung and colorectal cancers. In Phase 2 trials for locally advanced pancreatic cancer, Silexion's LODER™ platform showed a 9.3-month improvement in overall survival when combined with standard chemotherapy. Additionally, the objective response rate (ORR) increased from 20% with chemotherapy alone to 55% with the combination, and in some cases, tumors that were initially non-resectable became operable after treatment with LODER™. These results are especially encouraging given the limited options available for pancreatic cancer patients. SIL-204, is expected to enter Phase 2/3 clinical trials in 2025-2026. What makes Silexion particularly intriguing is its current market valuation. Valued at aproximatly just ~$9 million following its SPAC merger, the company’s valuation could be perceived as low when compared to some of its peers, especially given its innovative technology and promising clinical achievements. Some have wondered whether this low valuation has more to do with dynamics post-SPAC companies. If Silexion can report positive results in its later-stage trials, the company’s outlook could dramatically improve, reflecting the potential of its RNAi-based platform. Like NXP900, SIL-204 could potentially have vast applications across multiple KRAS-driven cancer types, making Silexion a company to watch closely as it advances through clinical development. Nuvectis Pharma: Targeting NSCLC and Beyond by Inhibiting SRC/YES1 Kinases Nuvectis Pharma (NASDAQ: NVCT) has been quietly making strides in the precision oncology sector, developing innovative therapies aimed at overcoming treatment resistance in hard-to-treat cancers. Its lead candidate, NXP900, targets NSCLC by inhibiting the SRC/YES1 kinases, which play critical roles in cancer cell survival and resistance to current therapies. This approach positions NXP900 as a potential game-changer in the treatment of NSCLC, particularly in patients who have developed resistance to EGFR and ALK inhibitors, such as AstraZeneca’s Tagrisso and Novartis’ Alecensa. NXP900 is still in the early stages of clinical development, currently undergoing Phase 1 trials. However, preclinical studies have already shown that it has strong anti-tumor activity in resistant NSCLC models. Even more promising is its potential application beyond NSCLC. Like Summit's ivonescimab, NXP900 focuses on resistance, but it also has broader applications due to its ability to target multiple cancer types driven by SRC/YES1 pathways. This versatility makes it a promising asset not just for NSCLC but also for other difficult-to-treat cancers like squamous cell carcinomas. In addition to NXP900, Nuvectis is advancing NXP800, another precision oncology candidate that is further along in the clinical development process. NXP800 is currently in Phase 1b trials, targeting ARID1a-mutated cancers such as ovarian and endometrial cancers. The early clinical data for NXP800 is promising, showing positive responses in patients with platinum-resistant ovarian cancer. With two strong candidates in the pipeline, Nuvectis is positioning itself as a formidable player in the precision oncology landscape. As Summit’s ivonescimab continues to gain attention, Nuvectis’ earlier-stage NXP900, with its NSCLC focus and beyond, could see similar success in the future if clinical results continue to trend positively. Scorpion Therapeutics: Pioneering Mutant-Selective Therapies Scorpion Therapeutics is redefining the frontier of precision oncology with its focus on delivering highly selective small molecules targeting validated and previously undruggable cancer mutations. Its lead candidate, STX-478, is a mutant-selective, allosteric PI3Kα inhibitor currently in Phase 1/2 trials for advanced solid tumors. Early data presented at the ESMO Congress 2024 highlighted its potential, with STX-478 demonstrating a 23% overall response rate in breast cancer and a 21% response rate across all tumor types, positioning it as a potentially best-in-class PI3Kα inhibitor. STX-478 is notable for its ability to spare wild-type PI3Kα activity in normal tissues, avoiding the toxicities seen with previous PI3Kα inhibitors, such as hyperglycemia and rash. Tumor reductions were seen in 72% of patients treated with STX-478 as a monotherapy, with circulating tumor DNA levels dropping in 86% of patients. This mutant-selective precision could help overcome the limitations of existing PI3Kα inhibitors, which have struggled with dose-limiting toxicities. In July 2024, Scorpion raised $150 million in a Series C financing round, co-led by Frazier Life Sciences and Lightspeed Venture Partners. The additional funding will support the advancement of STX-478 and other pipeline assets, positioning Scorpion for further clinical success. Scorpion’s pipeline includes a broad range of wholly-owned compounds that target both validated and novel cancer targets, positioning the company for future expansion into larger patient populations. As STX-478 progresses through clinical development, Scorpion is poised to become a significant player in the precision oncology space, making it another company worth watching closely. Optimistic Outlook for Precision Oncology The precision oncology space is experiencing a golden era of innovation, with companies like Summit Therapeutics, Nuvectis Pharma, Silexion Therapeutics, and Scorpion Therapeutics leading the charge. As the focus shifts towards targeted therapies that address resistance mechanisms, the market is increasingly favoring companies with novel approaches and broad applications. Summit’s meteoric rise has shown that there is tremendous potential for companies that can demonstrate efficacy in overcoming cancer resistance. While Summit has already captured much of the current attention, companies like Nuvectis, Silexion, and Scorpion, with their earlier-stage pipelines, offer exciting opportunities for the industry to keep a close eye on. As these companies continue to report clinical data and advance through trials, the potential for breakthroughs in treating some of the most difficult cancers grows stronger. With targeted therapies offering the possibility of overcoming resistance without the need for chemotherapy, the future of cancer treatment looks brighter than ever. For those in the oncology space, keeping a close eye on emerging players like Nuvectis, Silexion, and Scorpion could lead to transformative developments as the field of precision oncology continues to evolve. * * * This update may include speculative forward looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. the BioTech and Pharma industries are volatile and risky and readers are advised to seek out preffesional advice in the relevent feilds from licensed profesionals. This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [ https://justpaste.it/ch2qt/pdf ]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

September 19, 2024 07:45 AM Eastern Daylight Time

12345 ... 91